Table 1.
Clinical characteristics of the study cohorts
| Charité | Finland | Charité discovery | |
|---|---|---|---|
| Malignant | 62 | 76 | 152 |
| Age | 57 (50–72)*** | 58 (51–64)* | 59 (50–67)*** |
| Histology | |||
| Serous | 41 | 29 | 147 |
| Mucinous | 6 | 18 | |
| Endometrioid | 9 | 14 | 5 |
| Other | 6 | 15 | |
| Stage | |||
| I & II | 26 | 52 | 8 |
| III & IV | 33 | 22 | 133 |
| NA | 3 | 2 | 11 |
| Sample | |||
| Serum | 62 | 22 | 152 |
| Plasma | 54 | ||
| Borderline | 18 | 7 | |
| Age | 51 (44–57)NS | 63 (56–67)NS | |
| Histology | |||
| Serous | 13 | 5 | |
| Mucinous | 2 | 2 | |
| Other | 3 | ||
| Stage | |||
| I & II | 12 | 7 | |
| III & IV | 3 | ||
| NA | 3 | ||
| Sample | |||
| Serum | 18 | 7 | |
| Benign | 109 | 82 | 98 |
| Age | 49 (40–58) | 62 (56–69) | 41 (31–55) |
| Diagnosis | |||
| Other | 7 | 2 | 43 |
| Uterine fibroid | 7 | 1 | 25 |
| Cyst | 4 | 9 | 1 |
| Cystic teratoma | 12 | 8 | 5 |
| Functional cyst | 22 | ||
| Inclusion cyst | 3 | ||
| Endometrioid cyst | 5 | ||
| Non-ovarian cyst | 4 | ||
| Cystadenoma | 32 | 2 | 4 |
| Mucinous cystadenoma | 3 | 2 | |
| Cystadenofibroma | 7 | 10 | 2 |
| Serous cystadenoma | 34 | 3 | |
| Brenner tumour | 1 | 2 | 1 |
| Fibroma/thecoma | 5 | ||
| Fibroadenoma | 1 | ||
| Incomplete abortion | 5 | ||
| Adnexitis | 5 | ||
| Endometriosis | 9 | 1 | 2 |
| Sample | |||
| Serum | 109 | 82 | 98 |
NS not significant
For age, the values represent median and interquartile range and p-values in the comparison against the control group are denoted as follows: ***p < 0.001; **p < 0.01; *p < 0.05